Alignment Healthcare, Inc.

Fundamentals6.0
Price Action5.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Thin margins
  • Recent quarterly loss
  • Strong cash reserves

AI
AI Summary

6.0

ALHC has shifted from a pure enrollment growth story to a scaled Medicare Advantage operator where margin expansion via AVA/tech-enabled care and gross‑profit‑per‑member improvement—not membership alone—will determine valuation, so investors should condition their thesis on the company consistently delivering realized gross profit per member and durable adjusted EBITDA/FCF. Key actionable watchpoints: verify sequential gross‑profit‑per‑member beats, sustained positive free cash flow beyond seasonal swings, and whether RADV/Part D adjustments or insider selling abate before assuming current rich multiples.

MarginInflection
PolicyRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Thin margins
  • Recent quarterly loss
  • Strong cash reserves

ALHC delivers scale and annual free cash flow but suffers from very thin margins, a recent quarterly loss, high leverage versus equity, and rich valuation multiples—raising short‑term operating and valuation risk.

Leverage
CashStrength

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last-month SMA
  • Near-oversold RSI
  • Defined support zone

ALHC is in a short-term downtrend, trading below its last-month SMA (~$18.64) with RSI ~32 and immediate support at $16.99–$17.12 versus resistance near $20.40 and heavier at $22.89.

bearish
tactical
Support Level: $16.99–$17.12
Resistance Level: $20.40; heavier at $22.89

Price fell from the last-month

Sentiment & News

6.0

Key News Insights:

  • Beat guidance
  • Secondary offering
  • Institutional reshuffle

Alignment Healthcare beat Q4/FY2025 guidance and EPS estimates but saw an intraday sell-off amid active institutional repositioning and a large underwritten secondary by a prior major holder.

Outperformed
InsiderSell

The operational beat is positive, but the sizable secondary and heavy insider selling create near-term downward pressure on the stock despite improved metrics